Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis

European Journal of Haematology

Volumn 88, Issue 2, 2012, Pages 144-153

  Hopfer, Olaf ^a   Nolte, Florian ^b   Mossner, Maximilan ^a   Komor, Martina ^c   Kmetsch, Anke ^a   Benslasfer, Ouidad ^a   Reißmann, Monika ^d   Nowak, Daniel ^b   Hoelzer, Dieter ^c   Thiel, Eckhard ^a   Hofmann, Wolf Karsten ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

BCLxl; DLK1; DNA methylation; Erythropoiesis; GATA1; Hematopoietic stem cells; HES1; MDS; Notch1

Indexed keywords

CD34 ANTIGEN; MEMBRANE RECEPTOR; NOTCH1 RECEPTOR; PROTEIN BCL XL; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR HES 1;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DYSERYTHROPOIESIS; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METHYLATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCL-X PROTEIN; DNA METHYLATION; EPIGENESIS, GENETIC; ERYTHROPOIESIS; FEMALE; GATA1 TRANSCRIPTION FACTOR; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84855860977     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01715.x     Document Type: Article

References (82)

1. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712-7.
2. Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008;87:777-95.
3. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114:2393-400.
4. Nimer SD. MDS: a stem cell disorder - but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematology Am Soc Hematol Educ Program 2008:43-51.
5. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001;112:714-26.
6. Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005;106:247-53.
7. Zheng J, Kitajima K, Sakai E, et al. Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood 2006;107:520-7.
8. Galloway JL, Wingert RA, Thisse C, et al. Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell 2005;8:109-16.
9. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991;349:257-60.
10. Simon MC. Transcription factor GATA-1 and erythroid development. Proc Soc Exp Biol Med 1993;202:115-21.
11. Lowry JA, Mackay JP. GATA-1: one protein, many partners. Int J Biochem Cell Biol 2006;38:6-11.
12. Rodriguez P, Bonte E, Krijgsveld J, et al. GATA-1 forms distinct activating and repressive complexes in erythroid cells. EMBO J 2005; 24:2354-66.
13. Welch JJ, Watts JA, Vakoc CR, et al. Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 2004;104:3136-47.
14. Bartunek P, Kralova J, Blendinger G, et al. GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter. Oncogene 2003;22:1927-35.
15. Rekhtman N, Radparvar F, Evans T, et al. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 1999;13:1398-411.
16. Del Vecchio GC, Giordani L, De Santis A, et al. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol 2005;114:113-6.
17. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999;274:22165-9.
18. McDevitt MA, Shivdasani RA, Fujiwara Y, et al. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997; 94:6781-5.
19. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003;194:237-55.
20. Fischer A, Gessler M. Delta-Notch - and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 2007;35:4583-96.
21. Sasai Y, Kageyama R, Tagawa Y, et al. Two mammalian helix-loop-helix factors structurally related to Drosophila hairy and Enhancer of split. Genes Dev 1992;6:2620-34.
22. Gregory T, Yu C, Ma A, et al. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999;94:87-96.
23. Kuo YY, Chang ZF. GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription. Mol Cell Biol 2007;27:4261-72.
24. Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-71.
25. Artavanis-Tsakonas S, Muskavitch MA, Yedvobnick B. Molecular cloning of Notch, a locus affecting neurogenesis in Drosophila melanogaster. Proc Natl Acad Sci USA 1983;80:1977-81.
26. Ellisen LW, Bird LW, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61.
27. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33:416-21.
28. Radtke F, Schweisguth F, Pear W. The Notch 'gospel'. EMBO Rep 2005;6:1120-5.
29. Kumano K, Chiba S, Shimizu K, et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 2001;98:3283-9.
30. Lam LT, Romchini C, Norton J, et al. Suppression of erythroid but not megakaryocytic differentiation of human K562 erythroleukemic cells by notch-1. J Biol Chem 2000;275:19676-84.
31. Ishiko E, Matsumura I, Ezoe S, et al. Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1. J Biol Chem 2005;280:4929-39.
32. Henning K, Schroeder T, Schwanbeck R, et al. mNotch1 signaling and erythropoietin cooperate in erythroid differentiation of multipotent progenitor cells and upregulate beta-globin. Exp Hematol 2007;35:1321-32.
33. Sakajiri S, O'Kelly J, Yin D, et al. Dlk1 in normal and abnormal hematopoiesis. Leukemia 2005;19:1404-10.
34. Langer F, Stickel J, Tessema M, et al. Overexpression of delta-like (Dlk) in a subset of myelodysplastic syndrome bone marrow trephines. Leuk Res 2004;28:1081-3.
35. Bailey AM, Posakony JW. Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev 1995;9:2609-22.
36. Davis RL, Turner DL. Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 2001;20:8342-57.
37. Iso T, Sartorelli V, Poizat C, et al. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol Cell Biol 2001;21:6080-9.
38. Iso T, Sartorelli V, Chung G, et al. HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 2001;21:6071-9.
39. Elagib KE, Xiao M, Hussaini IM, et al. Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol 2004; 24:7779-94.
40. Doerfler W, Hoeveler A, Weisshaar B, et al. Promoter inactivation or inhibition by sequence-specific methylation and mechanisms of reactivation. Cell Biophys 1989;2:21-7.
41. Nyce J, Liu L, Jones PA. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res 1986;14:4353-67.
42. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114:2764-73.
43. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997;90:1403-9.
44. Hopfer O, Komor M, Koehler IS, et al. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp Hematol 2007; 35:712-23.
45. Quesnel B, Guillerm G, Vereecqe R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-90.
46. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113:1315-25.
47. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
48. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):21-9.
49. Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression. Oncogene 2009; 28:2046-50.
50. Komor M, Guller S, Baldus CD, et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells 2005;23:1154-69. Epub 2005 Jun 13.
51. Langer F, Stickel J, Tessema M, et al. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 2005;29:325-9.
52. Eisenberg E, Levanon EY. Human housekeeping genes are compact. Trends Genet 2003;19:362-5.
53. Economopoulou C, Pappa V, Papageorgiou S, et al. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Ann Hematol 2010;89:349-58.
54. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
55. Hellemans J, Mortier G, De Paepe A, et al. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
56. Ebert BL, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9.
57. Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 2008;142:57-64.
58. Mohamedali AM, Smith AE, Gaken J, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009;27:4002-6.
59. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42.
60. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10.
61. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-5.
62. Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the Ten-Eleven Translocation (TET)2 gene in familial myeloproliferative neoplasms. Blood 2009;114:1628-32.
63. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.
64. Hopfer O, Komor M, Koehler IS, et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 2009;33:434-42.
65. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153-8.
66. Tohyama K, Tohyama Y, Nakayama T, et al. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol 1995;91:795-9.
67. Craven SE, French D, Ye W, et al. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood 2005;105:3528-34.
68. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008;111:4297-308.
69. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: one is chosen. Leuk Res 2009;33:1011-6.
70. Onodera K, Takahashi S, Nishimura S, et al. GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and definitive erythropoiesis. Proc Natl Acad Sci USA 1997; 94:4487-92.
71. Raich N, Romeo PH. Erythroid regulatory elements. Stem Cells 1993;11:95-104.
72. Ney PA. Gene expression during terminal erythroid differentiation. Curr Opin Hematol 2006;13:203-8.
73. Takahashi S, Onodera K, Motohashi H, et al. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. J Biol Chem 1997;272:12611-5.
74. Ferreira R, Wai A, Shimizu R, et al. Dynamic regulation of Gata factor levels is more important than their identity. Blood 2007;109:5481-90.
75. Stirzaker C, Song JZ, Davidson B, et al. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004; 64:3871-7.
76. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
77. Tagoh H, Melnik S, Lefevre P, et al. Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro. Blood 2004;103:2950-5. Epub 2003 Dec 18.
78. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
79. Dalyot N, Fibach E, Ronchi A, et al. Erythropoietin triggers a burst of GATA-1 in normal human erythroid cells differentiating in tissue culture. Nucleic Acids Res 1993;21:4031-7.
80. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406-11.
81. Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115:706-15.
82. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009;27:361-8.